GSK And Pfizer RSV Vaccines Get US Recommendation – But Big Decisions On Pricing Yet To Come

Will Pfizer Undercut Rival?

GSK and Pfizer have both raised their price ranges based on longer-term efficacy data for their RSV vaccines, but Pfizer may choose to undercut on price in order to win market share against its rival’s more favorable data.

Vaccines

The first two respiratory syncytial virus (RSV) vaccines for older people, GSK’s Arexvy and Pfizer’s Abrysvo have been recommended by a key US panel, but reservations its experts expressed about the products will present a barrier for uptake.

One key issue was price and cost effectiveness, as neither company was willing to provide a definitive price for their...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip